Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
45.2M
-
Number of holders
-
95
-
Total 13F shares, excl. options
-
28M
-
Shares change
-
+1.83M
-
Total reported value, excl. options
-
$622M
-
Value change
-
+$47.6M
-
Put/Call ratio
-
0.37
-
Number of buys
-
54
-
Number of sells
-
-50
-
Price
-
$22.21
Significant Holders of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) as of Q4 2022
120 filings reported holding FDMT - 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2022.
4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) has 95 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28M shares
of 45.2M outstanding shares and own 61.98% of the company stock.
Largest 10 shareholders include BVF INC/IL (4.01M shares), VIKING GLOBAL INVESTORS LP (3.94M shares), Deep Track Capital, LP (2.66M shares), BlackRock Inc. (2.51M shares), JANUS HENDERSON GROUP PLC (1.47M shares), MORGAN STANLEY (1.46M shares), VANGUARD GROUP INC (1.27M shares), STATE STREET CORP (1.24M shares), ArrowMark Colorado Holdings LLC (982K shares), and HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND (774K shares).
This table shows the top 95 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.